Are we expecting another Perlegen announcement on Monday ??
MOUNTAIN VIEW, Calif., Dec. 20 /PRNewswire/ -- Perlegen Sciences, Inc., a privately-held genetics company, announced today a research collaboration with Pfizer Inc to discover the human genetic contributions to cardiovascular disease. The goal of the collaboration is to identify variations in DNA that bring about cardiovascular disease, and to use those genetic discoveries to enable the research and development of new pharmaceutical and diagnostic products.
Perlegen will employ its high-density genotyping technologies and knowledge of human genetic variation to identify genes and other genetic loci associated with cardiovascular disease. Financial terms of the collaboration were not disclosed.
Cardiovascular disease is the leading cause of death in the Western world, and is expected to become the leading cause of death worldwide by 2020. In the United States, almost one million people die of cardiovascular disease each year, and about 61 million live with this disease.
"Identifying the primary genetic determinants of cardiovascular disease promises to accelerate the search for new pharmaceutical agents that act on the causes of this global killer," said Brad Margus, CEO of Perlegen. "We are pleased to collaborate with Pfizer, a leader in the research and development of drugs that effectively treat cardiovascular disease." |
